EXPERT INTERVIEW: Focus on METex14 in Advanced NSCLC
Release date: 09-12-2024
Expiration date: 09-12-2025
In recent years, precision medicine for lung cancer has evolved rapidly. The use of advanced testing technology for genomic profiling in tissue and plasma (e.g. next generation sequencing, NGS) has led to the identification of new actionable molecular drivers, including MET exon 14 (METex14) skipping mutations and other alterations. Several new targeted therapies have recently entered clinical practice based on clinically meaningful efficacy and a favorable safety profile for METex14 skipping mutations.
However, despite these advances, the molecular testing in clinical practice, especially for uncommon alterations, remains suboptimal and available methods are not used appropriately. Consequently, patients may not receive optimal treatment regimens. In addition, practicing physicians often don’t feel confident in interpreting NGS results, treatment selection/sequencing, and managing adverse events (AEs) to targeted therapy.
Dr. Xiuning Le from MD Anderson Cancer Center will provide answers to 9 questions focusing on METex14 in advanced NSCLC, to share her insights and clinical practice.
This expert interview is available with subtitles in English and Chinese.
Faculty
Xiuning Le, MD, PhD
MD Anderson Cancer Center
The University of Texas
Houston, United States
Xiuning Le is a tenured Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas M.D. Anderson Cancer Center. Dr. Le received her M.D. from Peking Union Medical College in 2003, and her Ph.D. from Harvard Medical School in 2010. Her research focuses on cancer genomics and precision medicine with an expertise in cancer genetics and genomics, signaling pathway analysis, and disease modelling. She is also active in translational research. Dr. Le is the Principal Investigator of multiple large clinical trials on oncogene-driven lung cancer and leads many clinical trials as key investigator, including trials that have resulted in FDA approvals of novel targeted therapy and changes in standard of care treatments. Dr. Le has published more than 90 articles in peer-reviewed journals in the field of lung cancer and presented her work at many international conferences, including AACR, ASCO, WCLC, ESMO, etc. She has received numerous grants and awards, such as the ASCO Young Investigator Award, the V Foundation Clinical Investigator Award, and the Damon Runyon Clinical Investigator Award. Currently, Dr. Le is concentrating on investigating oncogene-driven lung cancer, such as EGFR, HER2 and METex14, the mechanisms of resistance and new combinations that overcome resistance, and the new applications of immunotherapy in lung cancer.
- Focus on METex14 in Advanced NSCLC | Xiuning Le, MD, PhD
The proposed educational activity is designed specifically for medical oncologists, pulmonologists, pathologists, oncology fellows, and other healthcare professionals involved in the management of patients with lung cancer in the APAC region and China.
Upon completion of this educational activity, participants should be able to:
- Assess broad molecular genomic profiling techniques, such as NGS (in tissue and plasma) to optimize detection approaches for METex14 skipping mutations
- Highlight the importance of early detection of METex14 skipping mutations and subsequent frontline use of targeted therapy
- Evaluate optimal treatment strategies for selective MET TKIs in first-line (1L) and later-line patients with METex14 skipping
- Optimize AE management for MET TKIs to maximize clinical outcomes
- Investigate the latest advancements in predictive biomarkers, identification of resistance mechanisms, and strategies to overcome them related to MET TKI therapies
- Assess ongoing trials in combination therapies involving MET TKIs and explore their role in perioperative settings
- Discuss optimal solutions for treating patients who have progressed after initial treatment with EGFR TKIs but have been identified with MET amplification
This activity is provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve the competence and performance of learners in order to improve patient care. There is no fee for this activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Xiuning Le has received honoraria for advisor or consultant roles from Eli Lilly, EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Regeneron, Boehringer Ingelheim, Hengrui Therapeutics, Bayer, Teligene, Taiho, Daiichi Sankyo, Janssen, Blueprint Medicines, Sensei Biotherapeutics, SystImmune, ArriVent, Abion, BlossomHill, and Abbvie. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.